M F Ugarte-Gil1, R V Gamboa-Cárdenas2, F Zevallos2, M Medina2, J M Cucho-Venegas2, R A Perich-Campos3, J L Alfaro-Lozano2, Z Rodriguez-Bellido3, G S Alarcón4, C A Pastor-Asurza3. 1. Servicio de Reumatología, Hospital Nacional Guillermo Almenara Irigoyen, Perú Universidad Científica del Sur, Perú manuel_ugarte@yahoo.com. 2. Servicio de Reumatología, Hospital Nacional Guillermo Almenara Irigoyen, Perú 3. Servicio de Reumatología, Hospital Nacional Guillermo Almenara Irigoyen, Perú Universidad Nacional Mayor de San Marcos, Lima, Perú 4. Department of Medicine, Division of Clinical Immunology and Rheumatology, School of Medicine, The University of Alabama at Birmingham, USA.
Abstract
OBJECTIVE: to determine whether prolactin levels are independently associated with disease damage in systemic lupus erythematosus (SLE) patients. METHODS: these cross-sectional analyses were conducted in SLE patient members of the Almenara Lupus Cohort who were seen between January 2012 and June 2013. Disease damage was ascertained with the System Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index (SDI). Prolactin was measured in ng/ml. The association between prolactin levels and the SDI (total and its domains) was evaluated using Spearman's correlation. Subsequently, adjusted Poisson regression models were performed to evaluate these associations. RESULTS: 160 patients were included. 147 (91.9%) were female; their median age at diagnosis was 33.4 (interquartile range (IQR): 26.0-44.3) years; their disease duration was 5.5 (IQR: 2.6-9.7) years. The median prolactin value was 16.8 (IQR: 11.8-24.5) ng/ml. After adjusting for confounders in the Poisson regression model the estimated rate ratios (RR) and 95% confidence interval (CI) for each 10 ng/ml increment of prolactin were 1.13 (95% CI 1.60-1.20, p<0.001) for the total SDI score, 1.15 (1.03-1.28, p=0.003) for the renal domain and 1.41 (1.11-1.79, p=0.003) for the cardiac/peripheral vascular domains. CONCLUSIONS: there was a positive association between prolactin levels and the SDI (overall and its renal and cardiac/peripheral vascular domains), independently of other well-known risk factors.
OBJECTIVE: to determine whether prolactin levels are independently associated with disease damage in systemic lupus erythematosus (SLE) patients. METHODS: these cross-sectional analyses were conducted in SLEpatient members of the Almenara Lupus Cohort who were seen between January 2012 and June 2013. Disease damage was ascertained with the System Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index (SDI). Prolactin was measured in ng/ml. The association between prolactin levels and the SDI (total and its domains) was evaluated using Spearman's correlation. Subsequently, adjusted Poisson regression models were performed to evaluate these associations. RESULTS: 160 patients were included. 147 (91.9%) were female; their median age at diagnosis was 33.4 (interquartile range (IQR): 26.0-44.3) years; their disease duration was 5.5 (IQR: 2.6-9.7) years. The median prolactin value was 16.8 (IQR: 11.8-24.5) ng/ml. After adjusting for confounders in the Poisson regression model the estimated rate ratios (RR) and 95% confidence interval (CI) for each 10 ng/ml increment of prolactin were 1.13 (95% CI 1.60-1.20, p<0.001) for the total SDI score, 1.15 (1.03-1.28, p=0.003) for the renal domain and 1.41 (1.11-1.79, p=0.003) for the cardiac/peripheral vascular domains. CONCLUSIONS: there was a positive association between prolactin levels and the SDI (overall and its renal and cardiac/peripheral vascular domains), independently of other well-known risk factors.
Authors: Paola A Zeña-Huancas; Haydee Iparraguirre-López; Rocío V Gamboa-Cárdenas; Cristina Reátegui-Sokolova; Francisco Zevallos-Miranda; Mariela Medina-Chinchon; Victor R Pimentel-Quiroz; Claudia Elera-Fitzcarrald; Omar Sarmiento-Velasquez; Jorge M Cucho-Venegas; José L Alfaro-Lozano; Zoila J Rodríguez-Bellido; César A Pastor-Asurza; Risto A Perich-Campos; Graciela S Alarcón; Manuel F Ugarte-Gil Journal: Clin Rheumatol Date: 2018-12-12 Impact factor: 2.980
Authors: Luis J Jara; Gabriela Medina; Miguel A Saavedra; Olga Vera-Lastra; Honorio Torres-Aguilar; Carmen Navarro; Monica Vazquez Del Mercado; Luis R Espinoza Journal: Immunol Res Date: 2017-04 Impact factor: 2.829
Authors: C Reátegui-Sokolova; Manuel F Ugarte-Gil; Rocío V Gamboa-Cárdenas; Francisco Zevallos; Jorge M Cucho-Venegas; José L Alfaro-Lozano; Mariela Medina; Zoila Rodriguez-Bellido; Cesar A Pastor-Asurza; Graciela S Alarcón; Risto A Perich-Campos Journal: Clin Rheumatol Date: 2017-01-18 Impact factor: 2.980
Authors: Manuel Francisco Ugarte-Gil; Rocio Violeta Gamboa-Cardenas; Cristina Reátegui-Sokolova; Victor Román Pimentel-Quiroz; Mariela Medina; Claudia Elera-Fitzcarrald; Francisco Zevallos; Cesar Augusto Pastor-Asurza; Jeniffer Lofland; Federico Zazzetti; Chetan S Karyekar; Graciela S Alarcón; Risto Alfredo Perich-Campos Journal: Lupus Sci Med Date: 2022-02
Authors: Manuel Francisco Ugarte-Gil; Rocio Violeta Gamboa-Cardenas; Cristina Reátegui-Sokolova; Victor Román Pimentel-Quiroz; Mariela Medina; Claudia Elera-Fitzcarrald; Francisco Zevallos; Cesar Augusto Pastor-Asurza; Federico Zazzetti; Chetan S Karyekar; Graciela S Alarcón; Risto Alfredo Perich-Campos Journal: Lupus Sci Med Date: 2022-03
Authors: María Victoria Legorreta-Haquet; Karina Chávez-Rueda; Luis Chávez-Sánchez; Hernando Cervera-Castillo; Edgar Zenteno-Galindo; Leonor Barile-Fabris; Rubén Burgos-Vargas; Everardo Álvarez-Hernández; Francisco Blanco-Favela Journal: Medicine (Baltimore) Date: 2016-02 Impact factor: 1.889